Periodontal wound healing following GTR therapy of dehiscence-type defects in the monkey: short-, medium- and long-term healing
These include: Persistent fatigue, cold intolerance, or constipation (suggesting hypothyroidism) Excessive thirst, increased urination, or blurred vision (indicating poor glycaemic control) Abdominal pain, nausea, or vomiting (potential pancreatitis, a rare but serious adverse effect) Right upper quadrant pain, jaundice, pale stools, or dark urine (possible gallbladder disease, which has increased risk with GLP-1 receptor agonists) [1] [2] New visual symptoms including floaters or blurred vision (potential diabetic retinopathy complications) Mood changes, particularly low mood or increased anxiety New or worsening oedema in the legs, ankles, or face Lack of expected weight loss after three to six months at therapeutic doses should also prompt discussion with your healthcare provider
2022 R&D Spend: For the year ended March 31, 2023, Daiichi Sankyo spent 341.57 billion JPY ($2.60 billion USD) on R&D, a 31.21 percent increase from the 260.33 billion JPY ($2.37 billion USD) the company spent on R&D for the year ended March 31, 2022
While programs exist to lower costs, patients need to educate themselves on the pricing and access options to make informed decisions about pursuing this treatment
